Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
55 Results for "
Gsdmd
" in MedChemExpress (MCE) Product Catalog:
Products (55)
55 Results for "Gsdmd" in MCE Product Catalog:
Cat. No.: HY-P704049A
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Gsdmd; Gasdermin Domain Containing 1; Prev. GsdmdC1; FLJ12150; DF5L; DFNA5L; Gasdermin Domain-Containing Protein 1; FKSG10; Gasdermin D; Gasdermin-D
Species:
Human
Source:
E. coli
Cat. No.: HY-P83706A
Synonyms: DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; Gsdmd_HUMAN; GsdmdC 1; GsdmdC1; Gasdermin-D, N-terminal; Gsdmd-NT; hGsdmd-NTD; Gasdermin-D, C-terminal; Gsdmd-CT; hGsdmd-CTD.
Cat. No.: HY-181168
Target:
Research Areas:
Lb54 is a caspase-3 and caspase-7 activator with an EC50 of 660.9 nM for human procaspase-3. Lb54 activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at aspartic acid residue 87 to generate a p10 fragment, preventing formation of the pore-forming p30 fragment of GSDMD. Lb54 suppresses GSDMD-mediated pyroptosis through caspase-3/7 activation, thereby attenuating inflammatory responses and conferring protection against sepsis. Lb54 alleviates acute lung injury, and inhibited systemic inflammation by restraining the maturation of monocyte-derived dendritic cells. Lb54 can be used for the research of sepsis .
Cat. No.: HY-189671
Target:
Research Areas:
PGC-01 is a PROTAC degrader targeting GSDMD, with a DC50 of 3.32 μM in THP-1 cells. PGC-01 mediates CRBN-dependent ubiquitination and proteasomal degradation of full-length GSDMD, blocking pyroptosis at the source. PGC-01 concentration-dependently inhibits Nigericin (HY-127019)-induced macrophage pore formation, cell death, and IL-1β release. PGC-01 can be used for colitis research .
Cat. No.: HY-111674R
CAS No.: 2407782-01-6
Target:
Research Areas:
LDC7559 (Standard) is the analytical standard of LDC7559 (HY-111674). This product is intended for research and analytical applications. LDC7559 is a gasdermin D (GSDMD) inhibitor via blocKing neutrophil extracellular trap (NET) in the late stages .
Cat. No.: HY-P11603
Target:
Research Areas:
Cat. No.: HY-N21740
CAS No.: 219793-20-1
Cat. No.: HY-185207
CAS No.: 3034207-17-2
Target:
CQ80 is a PEPD/XPNPEP1 inhibitor and selective CARD8 inflammasome activator. CQ80 has IC50 values of 0.91 μM for PEPD, 43 μM for XPNPEP1. CQ80 promotes the accumulation of Xaa-Pro peptides by inhibiting PEPD and XPNPEP1, releases the fragment of CARD8 for inflammasome formation, and induces pyroptosis via GSDMD cleavage. CQ80 can be used for research on inflammasome, CARD8-expressing cancer cells, HIV-1-infected cell clearance, acute myeloid leukemia (AML) .
Cat. No.: HY-13453R
CAS No.: 19542-67-7
Synonyms: BAY 11-7821 (Standard)
Research Areas:
BAY 11-7082 (Standard) is the analytical standard of BAY 11-7082 (HY-13453). This product is intended for research and analytical applications. BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .
Cat. No.: HY-180830
CAS No.: 2361570-54-7
Research Areas:
NLRP3-IN-86 (Compound 8a), a derivative of Songorine (HY-N2080), is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS (HY-D1056)- and Nigericin (HY-127019)-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation .
Cat. No.: HY-189386
CAS No.: 3081319-75-4
Research Areas:
Pyroptosis inducer-1 is a pyroptosis inducer. Pyroptosis inducer-1 promotes STING phosphorylation, NF-κB activation, caspase-1-dependent pyroptosis, GSDMD cleavage, mitochondrial membrane potential disruption, ROS production, S phase cell cycle arrest, ER stress, calcium release, and immunogenic cell death accompanied by CRT exposure, HMGB1 release, and ATP secretion. Pyroptosis inducer-1 enters cancer cells via endocytosis and accumulates in mitochondria and endoplasmic reticulum. Pyroptosis inducer-1 increases dendritic cells and CD8 + T cells while decreasing regulatory T cells. Pyroptosis inducer-1 can be used for breast cancer research .
Cat. No.: HY-100573R
CAS No.: 1360614-48-7
Necrosulfonamide (Standard) is the analytical standard of Necrosulfonamide (HY-100573). This product is intended for research and analytical applications. Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways .
Cat. No.: HY-19309
CAS No.: 223756-43-2
Synonyms: A-216546 hydrochloride
Target:
Endothelin Receptor NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Pyroptosis Interleukin Related
Research Areas:
ABT-546 (A-216546) hydrochloride is an orally active ETA receptor antagonist, with Ki values of 0.46 nM and 13000 nM for human ETA and ETB receptors, respectively, and exhibits >25000-fold selectivity over the ETB receptor. ABT-546 hydrochloride effectively inhibits ET-1 (HY-P0202)-induced phosphoinositide hydrolysis (IC50 = 0.59 nM) and arachidonic acid release (IC50 = 3.03 nM), and antagonizes ET-1-induced contraction in isolated vascular rings. ABT-546 hydrochloride crosses the placental barrier but shows extremely low fetal exposure, with a favorable safety profile. ABT-546 hydrochloride inhibits ET-1-induced pressor response and downregulates the NLRP3/ROS/GSDMD-mediated pyroptosis pathway. ABT-546 hydrochloride can be used for research on abdominal aortic aneurysm .
Cat. No.: HY-182066
Target:
Research Areas:
Photosensitizer-9 is an iridium (III)-based photosensitizer with anti-melanoma activity. Photosensitizer-9 exhibits significant phototoxicity (IC50=0.98 μM) and an ideal phototoxicity index (PI=3.05). Under light irradiation, Photosensitizer-9 generates large amounts of intracellular •OH in an oxygen-independent manner. Photosensitizer-9 mediates photodynamic therapy under hypoxic conditions and synergistically activates PANoptosis (by upregulating cleaved Caspase-3, GSDMD-N, p-MLKL), ferroptosis (by disrupting the GSH-GPX4-LPO axis), apoptosis, pyroptosis and necroptosis in melanoma cells. Photosensitizer-9 induces immunogenic cell death by promoting the release of damage-associated molecular patterns under hypoxic conditions and increases the maturation rate of dendritic cells. Photosensitizer-9 reduces tumor volume in melanoma-bearing mice. Photosensitizer-9 is applicable to relevant studies on melanoma .
Cat. No.: HY-P11935
CAS No.: 2410535-57-6
Target:
Wnt Apoptosis Pyroptosis NOD-like Receptor (NLR) Caspase Bcl-2 Family β-catenin GSK-3 Interleukin Related
Research Areas:
RR-171 is an amino acid polypeptide and an inhibitor of the Wnt signaling pathway. RR-171 reduces the expression levels of Wnt-1, GSK3β and β-catenin. RR-171 induces apoptosis (Apoptosis) in pancreatic cancer cells, which is characterized by an increased Bax/Bcl-2 ratio, activation of Caspase-3/7/9, and increased Cleaved-PARP; this pro-apoptotic effect can be partially reversed by Z-VAD-FMK (HY-16658B). RR-171 also induces pyroptosis (Pyroptosis) in pancreatic cancer cells, which is manifested by activation of the NLRP-3 inflammasome, activation of Caspase-1, cleavage of GSDMD, upregulation of IL-1β and IL-18, and increased LDH release; this pro-pyroptotic effect can be partially reversed by VX-765 (HY-13205). RR-171 inhibits the viability, proliferation and colony formation of pancreatic cancer cells, with low cytotoxicity against normal cells. RR-171 downregulates the expression of Ki-67 and PCNA in tumor tissues in vivo, with favorable biosafety. RR-171 can be used in studies related to pancreatic cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
